ReviewJournal of hepatocellular carcinoma2026
Hepatocellular Carcinoma Precursor Lesions: From Pathological Basis to Risk Stratification and Precision Intervention.
Review in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) predominantly arises against a background of chronic liver disease and cirrhosis, with its development typically following the three-step pattern of "hepatitis-cirrhosis-liver cancer." Hepatocellular carcinoma precursor lesions represent a critical stage in this process and constitute a vital window for early diagnosis and targeted intervention. This review aims to systematically summarize the pathological basis, malignant potential, diagnostic approaches, risk stratification strategies, and precision intervention perspectives of HCC precursor lesions. Specifically, we review the pathological characteristics and malignant potential of HCC precursor lesions such as hepatocellular large/small cell transformation, dysplastic foci (DF), low/high-grade dysplastic nodules (LGDN/HGDN), and β-catenin-activated hepatocellular adenoma. We further summarize the application value and limitations of ultrasound/contrast-enhanced ultrasound (US), computed tomography (CT), and Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) in screening and differential diagnosis. In addition, we discuss the progress in serum markers such as AFP, AFP-L3, DCP, and GP73, as well as liquid biopsy markers including CTC, ctDNA methylation, cfRNA, and tumor metabolites. We also outline the application of multivariable risk models like age-Male-ALBI-Platelet (aMAP), Gender-Age-AFP-L3-AFP-DCP (GALAD), and THRI in risk stratification and dynamic monitoring of high-risk populations. Finally, we review current treatment and follow-up strategies for HCC precursor lesions and explore the potential of radiomics, artificial intelligence, and multi-omics integration to improve risk assessment and diagnostic support, while also discussing their current limitations and the gap between research findings and routine clinical implementation. Overall, HCC precursor lesions represent an important target for early surveillance and precise intervention, and the integrated application of pathology, imaging, biomarkers, risk models, and emerging technologies may improve early identification, individualized management, and future translational research in HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.